We are live on ! Find out more
Alyeska Investment Group

Alyeska Investment Group Portfolio holdings

AUM $35.4B
1-Year Est. Return 33.54%
This Fund
S&P 500
This Quarter Est. Return
+8.66%
1 Year Est. Return
+33.54%
3 Year Est. Return
+101.08%
5 Year Est. Return
+102.29%
10 Year Est. Return
+544.32%
AUM
$19.6B
AUM Growth
+$2.1B
Cap. Flow
+$943M
Cap. Flow %
4.81%
Top 10 Hldgs %
14.75%
Holding
739
New
183
Increased
150
Reduced
140
Closed
230

Top Sells

Rank Stock Value
1
AAPL icon
Apple
AAPL
+$263M
2
TEL icon
TE Connectivity
TEL
+$242M
3
ZM icon
Zoom
ZM
+$242M
4
QCOM icon
Qualcomm
QCOM
+$208M
5
META icon
Meta Platforms (Facebook)
META
+$190M

Sector Composition

Rank Sector Weight
1 Technology 23.88%
2 Consumer Discretionary 18.76%
3 Healthcare 12.63%
4 Industrials 12.54%
5 Financials 8.4%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
JCI icon
426
Johnson Controls International
JCI
$91.3B
$1.81M 0.01%
+23,318
New +$1.64M
CDW icon
427
CDW
CDW
$17.1B
$1.79M 0.01%
+7,913
New +$1.76M
SGI
428
Somnigroup International
SGI
$13.6B
$1.76M 0.01%
+32,254
New +$1.64M
BWMN icon
429
Bowman Consulting
BWMN
$743M
$1.76M 0.01%
72,955
-67,045
-48% -$1.85M
CVE icon
430
Cenovus Energy
CVE
$54.5B
$1.71M 0.01%
101,951
-1,435,896
-93% -$26.6M
TENB icon
431
Tenable Holdings
TENB
$4.04B
$1.68M 0.01%
41,547
+29,035
+232% +$1.21M
RGLS
432
DELISTED
Regulus Therapeutics
RGLS
$1.63M 0.01%
1,037,500
+100,000
+11% +$165K
LZ icon
433
LegalZoom.com
LZ
$973M
$1.59M 0.01%
250,000
-250,000
-50% -$1.64M
DTIL icon
434
Precision BioSciences
DTIL
$206M
$1.58M 0.01%
176,382
VRTX icon
435
Vertex Pharmaceuticals
VRTX
$133B
$1.56M 0.01%
+3,353
New +$1.61M
ARTV
436
Artiva Biotherapeutics
ARTV
$549M
$1.54M 0.01%
+100,000
New +$1.16M
EQR icon
437
Equity Residential
EQR
$24.7B
$1.48M 0.01%
+19,928
New +$1.44M
GB
438
DELISTED
Global Blue Group Holding
GB
$1.47M 0.01%
269,076
-91,038
-25% -$461K
NKLA
439
DELISTED
Nikola Corporation Common Stock
NKLA
$1.46M 0.01%
319,792
NVNO
440
enVVeno Medical
NVNO
$6.78M
$1.43M 0.01%
+12,143
New +$2.23M
MGTX icon
441
MeiraGTx Holdings
MGTX
$1.21B
$1.38M 0.01%
330,182
CRUS icon
442
Cirrus Logic
CRUS
$6.11B
$1.36M 0.01%
+10,962
New +$1.45M
UBX
443
DELISTED
Unity Biotechnology
UBX
$1.35M 0.01%
920,013
CYTK icon
444
Cytokinetics
CYTK
$10.5B
$1.32M 0.01%
+25,000
New +$1.39M
GE icon
445
GE Aerospace
GE
$380B
$1.31M 0.01%
6,953
-3,722
-35% -$631K
HELP
446
Cybin Inc
HELP
$620M
$1.26M 0.01%
142,233
NAUT icon
447
Nautilus Biotechnolgy
NAUT
$110M
$1.26M 0.01%
441,018
TERN
448
DELISTED
Terns Pharmaceuticals
TERN
$1.25M 0.01%
+150,000
New +$1.23M
ELDN icon
449
Eledon Pharmaceuticals
ELDN
$284M
$1.25M 0.01%
500,000
IBTA icon
450
Ibotta
IBTA
$729M
$1.23M 0.01%
20,000

Similar funds

Alyeska Investment Group's Q3 2024 Portfolio in Review

As of Q3 2024, Alyeska Investment Group held 739 positions worth $19.6B, up 12% from $17.5B the previous quarter. Its ten largest holdings account for 15% of the portfolio.

Alyeska Investment Group deployed $943M of net new capital in Q3 2024, opening 183 new positions and adding to 150 existing holdings. Its largest new stake was Microsoft: 734,107 shares worth $316M.

By sector, the portfolio is most concentrated in Technology at 24% of assets, down from 25% a quarter earlier, followed by Consumer Discretionary and Healthcare.

On the sell side, the largest reduction was Zoom, an estimated $242M trimmed.

  • Alyeska Investment Group's largest Q3 2024 buy was Microsoft: 734,107 shares worth $316M.
  • Alyeska Investment Group added most to lululemon athletica in Q3 2024, an estimated $221M increase.
  • Alyeska Investment Group's biggest Q3 2024 reduction was Zoom, cutting an estimated $242M.
  • Alyeska Investment Group fully exited Apple in Q3 2024, selling an estimated $263M.
  • Alyeska Investment Group's ten largest holdings make up 15% of its $19.6B portfolio in Q3 2024.
  • Alyeska Investment Group opened 183 new positions and closed 230 in Q3 2024.
  • Alyeska Investment Group's portfolio value rose 12% quarter-over-quarter to $19.6B.

Based on Alyeska Investment Group's 13F filing for Q3 2024, filed 14 Nov 2024.